Gianluca Tomasello

Summary

Affiliation: Faculty of Medicine

Publications

  1. doi Targeted therapies in gastric cancer treatment: where we are and where we are going
    Gianluca Tomasello
    Oncology Division, Azienda Socio Sanitaria Territoriale di Cremona, Ospedale di Cremona, Viale Concordia 1, 26100, Cremona, Italy
    Invest New Drugs 34:378-93. 2016
  2. doi Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial
    Gianluca Tomasello
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100, Cremona, Italy
    Gastric Cancer 17:711-7. 2014
  3. doi Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib
    Gianluca Tomasello
    Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Crit Rev Oncol Hematol 75:110-21. 2010
  4. ncbi Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen
    Gianluca Tomasello
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Italy
    Tumori 96:48-53. 2010
  5. doi Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
    Matteo Dalla Chiesa
    Departments of Medical Oncology and Biostatistics, Azienda Ospedaliera di Cremona, Cremona, Italy
    Cancer Chemother Pharmacol 67:41-8. 2011
  6. ncbi A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
    Matteo Dalla Chiesa
    Medical Oncology, 2Surgery Division, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Tumori 93:244-7. 2007
  7. doi Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer
    Wanda Liguigli
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Cremona Italy
    Tumori . 2016
  8. doi Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer
    Rodolfo Passalacqua
    Divisione di Medicina e Oncologia Medica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy
    Cancer Immunol Immunother 59:553-61. 2010
  9. ncbi Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report
    Sebastiano Buti
    Oncology Division, University of Parma, Medical School, Parma, Italy
    Anticancer Drugs 18:297-300. 2007
  10. ncbi Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial
    Matteo Dalla Chiesa
    Oncology Division, Hospital of Cremona, Cremona, Italy
    Acta Biomed 78:204-9. 2007

Collaborators

Detail Information

Publications17

  1. doi Targeted therapies in gastric cancer treatment: where we are and where we are going
    Gianluca Tomasello
    Oncology Division, Azienda Socio Sanitaria Territoriale di Cremona, Ospedale di Cremona, Viale Concordia 1, 26100, Cremona, Italy
    Invest New Drugs 34:378-93. 2016
    ..These include drugs targeting EGFR, angiogenesis, c-MET, FGFR2, mTOR and immune checkpoints. ..
  2. doi Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial
    Gianluca Tomasello
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100, Cremona, Italy
    Gastric Cancer 17:711-7. 2014
    ..We report here the final results of a phase II study of chemotherapy with a modified TCF-dd regimen in locally advanced or metastatic gastric cancer (MGC)...
  3. doi Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib
    Gianluca Tomasello
    Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Crit Rev Oncol Hematol 75:110-21. 2010
    ..This article reviews the epidemiology, current treatment options and recent advances in the field, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases...
  4. ncbi Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen
    Gianluca Tomasello
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Italy
    Tumori 96:48-53. 2010
    ....
  5. doi Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
    Matteo Dalla Chiesa
    Departments of Medical Oncology and Biostatistics, Azienda Ospedaliera di Cremona, Cremona, Italy
    Cancer Chemother Pharmacol 67:41-8. 2011
    ..To evaluate a new strategy of two sequential, intensified chemotherapy regimens in metastatic gastric cancer...
  6. ncbi A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
    Matteo Dalla Chiesa
    Medical Oncology, 2Surgery Division, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Tumori 93:244-7. 2007
    ..The aim of this study was to evaluate chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI regimen) in metastatic gastric cancer...
  7. doi Safety and efficacy of dose-dense chemotherapy with TCF regimen in elderly patients with locally advanced or metastatic gastric cancer
    Wanda Liguigli
    Medical Oncology Division, Azienda Istituti Ospitalieri di Cremona, Cremona Italy
    Tumori . 2016
    ..To evaluate the efficacy and safety of dose-dense TCF in elderly (≥65 years) compared to younger patients...
  8. doi Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer
    Rodolfo Passalacqua
    Divisione di Medicina e Oncologia Medica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy
    Cancer Immunol Immunother 59:553-61. 2010
    ..88; 95% CI 0.60-1.31; p = 0.54). Toxicity was mainly limited to WHO grades 1 or 2. Chronic maintenance immunotherapy after disease progression is feasible, but does not significantly increase OS or the TFPTD...
  9. ncbi Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report
    Sebastiano Buti
    Oncology Division, University of Parma, Medical School, Parma, Italy
    Anticancer Drugs 18:297-300. 2007
    ..To the best of our knowledge, only seven other cases have been described in the literature, but we believe this serious adverse event induced by oxaliplatin is more frequent than this would suggest...
  10. ncbi Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial
    Matteo Dalla Chiesa
    Oncology Division, Hospital of Cremona, Cremona, Italy
    Acta Biomed 78:204-9. 2007
    ..To demonstrate the efficacy of 13-cis-retinoic acid (RA) or Interferon alpha-2a (IFN alpha-2a) with Tamoxifen (TAM) in the treatment of advanced breast cancer...
  11. doi Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial
    Wanda Liguigli
    Oncology Division, Istituti Ospitalieri di Cremona, Cremona, Italy
    Future Oncol 10:1549-57. 2014
    ..This article will review the main findings of the REGARD trial and discuss their potential impact on future treatment of metastatic gastric cancer. ..
  12. doi Jumping higher: is it still possible? The ALTTO trial challenge
    Gianluca Tomasello
    Institute Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Expert Rev Anticancer Ther 8:1883-90. 2008
    ..Overall, 8000 patients will be enrolled worldwide...
  13. doi Emerging combination therapies to overcome resistance in EGFR-driven tumors
    Margherita Ratti
    Medical Oncology Unit, Azienda Istituti Ospitalieri di Cremona, Cremona, Italy
    Anticancer Drugs 25:127-39. 2014
    ..Here, we describe some of the mechanisms of resistance to EGFR inhibitors and review the main innovations attempting to overcome these drawbacks. ..
  14. pmc New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
    Michele Ghidini
    Medical Department, Division of Oncology, ASST di Cremona, Ospedale di Cremona, Cremona, Italy
    Ther Clin Risk Manag 12:1009-15. 2016
    ..Balugrastim was well tolerated, with the only related adverse event being mild to moderate bone pain. The aim of this review is to summarize the currently available literature data on balugrastim. ..
  15. ncbi Immunotherapy options in metastatic renal cell cancer: where we are and where we are going
    Rodolfo Passalacqua
    Istituti Ospitalieri, Department of Internal Medicine, Medical Oncology Division, Viale Concordia 1, 26100, Cremona, Italy
    Expert Rev Anticancer Ther 6:1459-72. 2006
    ..Future research will not only need to make every effort to optimize the use of the new molecules and to define their efficacy precisely, but also to consider how to integrate these drugs with the traditional immunotherapy...
  16. doi Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity
    Fausto Petrelli
    aOncology Unit, Department of Oncology, ASST Bergamo Ovest, Treviglio BG bOncology Unit, Department of Oncology, ASST Ospedale di Cremona, Cremona, Italy
    Anticancer Drugs 28:133-141. 2017
    ..By providing a 50% ORR, such regimens may be particularly indicated for younger and fit patients for cytoreductive purposes (conversion therapy) or in case of symptomatic tumor burden...
  17. doi Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia
    Margherita Ratti
    Oncology Division, Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy
    Expert Rev Clin Pharmacol 8:15-24. 2015
    ..In fact, similar to pegfilgrastim, it has been demonstrated to reduce the duration of neutropenia and the occurrence of FN during chemotherapy safely. ..